Anticholinergic medications and risk of dementia in older adults: Where are we now?

References

• Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93(9):457–462.
   PubMed Web of Science ®Google Scholar
• Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335–348. .
   PubMed Web of Science ®Google Scholar
• Tune LE. Anticholinergic effects of medication in elderly patients.. J Clin Psychiatry. 2001;62 Suppl 21(Suppl 21):11–14.
   PubMedGoogle Scholar
• Sura SD, Carnahan RM, Chen H, et al. Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs Aging. 2013;30(10):837–844. .
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Mehta S, Sherer JT, et al. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging. 2010;27(12):987–997. .
   PubMed Web of Science ®Google Scholar
• Bhattacharya R, Chatterjee S, Carnahan RM, et al. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9(6):434–441. .
   PubMedGoogle Scholar
• McNeely SS, Bhattacharya R, Aparasu RR. Prevalence of anticholinergic use among older home health patients. J Clin Nurs. 2013;22(1–2):285–288.
   PubMed Web of Science ®Google Scholar
• Seifert R, Jamieson J, Gardner R Jr. Use of anticholinergics in the nursing home: an empirical study and review. Drug Intell Clin Pharm. 1983;17(6):470–473.
   PubMedGoogle Scholar
• Doraiswamy PM, Husain MM. Anticholinergic drugs and elderly people: a no brainer? Lancet Neurol. 2006;5(5):379–380.
   PubMed Web of Science ®Google Scholar
• Fink HA, Hemmy LS, Linskens EJ, et al. Diagnosis and Treatment of Clinical Alzheimer’s-Type Dementia: A Systematic Review. Comparative Effectiveness Review No. 223. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2015-00008-I.). 2020(AHRQ Publication No. 20-EHC003. Rockville, MD; Agency for Healthcare Research and Quality: 2020 April.
   Google Scholar
• Olde Rikkert MG, Rigaud AS, van Hoeyweghen RJ, et al. Geriatric syndromes: medical misnomer or progress in geriatrics? Neth J Med. 2003;61(3):83–87.
   PubMed Web of Science ®Google Scholar
• Kane RL, Shamliyan T, Talley K, et al. The association between geriatric syndromes and survival. J Am Geriatr Soc. 2012;60(5):896–904. .
   PubMed Web of Science ®Google Scholar
• By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674–694.
   PubMed Web of Science ®Google Scholar
• Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008;37(6):673–679.
   PubMed Web of Science ®Google Scholar
• Kuhn-Thiel AM, Weiss C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31(2):131–140.
   PubMed Web of Science ®Google Scholar
• Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099–1105. .
   PubMedGoogle Scholar
• Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–787. .
   PubMedGoogle Scholar
• Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–513. .
   PubMedGoogle Scholar
• Boustani M, Baker MS, Campbell N, et al. Impact and recognition of cognitive impairment among hospitalized elders. J Hosp Med. 2010;5(2):69–75. .
   PubMed Web of Science ®Google Scholar
• Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–1486. .
   PubMed Web of Science ®Google Scholar
• Summers WK. A clinical method of estimating risk of drug induced delirium. Life Sci. 1978;22(17):1511–1516. .
   PubMed Web of Science ®Google Scholar
• Sittironnarit G, Ames D, Bush AI, et al. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement Geriatr Cogn Disord. 2011;31(3):173–178. .
   PubMed Web of Science ®Google Scholar
• Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455–459. .
   PubMed Web of Science ®Google Scholar
• Ehrt U, Broich K, Larsen JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg. 2010;81(2):160. .
   PubMed Web of Science ®Google Scholar
• Duran CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69(7):1485–1496.
   PubMed Web of Science ®Google Scholar
• Klamer TT, Wauters M, Azermai M, et al. A Novel Scale Linking Potency and Dosage to Estimate Anticholinergic Exposure in Older Adults: the Muscarinic Acetylcholinergic Receptor ANTagonist Exposure Scale. Basic Clin Pharmacol Toxicol. 2017;120(6):582–590. .
   PubMed Web of Science ®Google Scholar
• Lozano-Ortega G, Johnston KM, Cheung A, et al. A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr. 2020;87:103885. .
   PubMed Web of Science ®Google Scholar
• Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–233.
   PubMed Web of Science ®Google Scholar
• Gray SL, Hanlon JT. Anticholinergic medication use and dementia: latest evidence and clinical implications. Ther Adv Drug Saf. 2016;7(5):217–224.
   PubMedGoogle Scholar
• Carrière I, Fourrier-Reglat A, Dartigues J-F, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med. 2009;169(14):1317–1324. .
   PubMedGoogle Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407. .
   PubMed Web of Science ®Google Scholar
• Jessen F, Wiese B, Bachmann C, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67(4):414–422. .
   PubMed Web of Science ®Google Scholar
• Jessen F, Kaduszkiewicz H, Daerr M, et al. Anticholinergic drug use and risk for dementia: target for dementia prevention. Eur Arch Psychiatry Clin Neurosci. 2010;260(Suppl 2):S111–5. .
   PubMedGoogle Scholar
• Andrade C. Anticholinergic Drug Exposure and the Risk of Dementia: there Is Modest Evidence for an Association but Not for Causality. J Clin Psychiatry. 2019;80(4). DOI:https://doi.org/10.4088/JCP.19f13000
   Google Scholar
• Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. Bmj. 2018;361:k1315.
   PubMedGoogle Scholar
• Coupland CAC, Hill T, Dening T, et al., Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med. 2019;179(8):1084–1093. .
   PubMed Web of Science ®Google Scholar
• Sheu JJ, Tsai M-T, Erickson SR, et al. Association between Anticholinergic Medication Use and Risk of Dementia among Patients with Parkinson’s Disease. Pharmacotherapy. 2019;39(8):798–808. .
   PubMed Web of Science ®Google Scholar
• Yang YW, Liu -H-H, Lin T-H, et al. Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus. PLoS One. 2017;12(4):e0175335. .
   PubMed Web of Science ®Google Scholar
• Cai X, Campbell N, Khan B, et al. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013;9(4):377–385. .
   PubMed Web of Science ®Google Scholar
• Campbell NL, Lane KA, Gao S, et al. Anticholinergics Influence Transition from Normal Cognition to Mild Cognitive Impairment in Older Adults in Primary Care. Pharmacotherapy. 2018;38(5):511–519. .
   PubMed Web of Science ®Google Scholar
• Aromataris E,MZE. JBI Manual for Evidence Synthesis; 2020. Available from https://synthesismanual.jbi.global.
   Google Scholar
• Andre L, Gallini A, Montastruc F, et al. Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study. Br J Clin Pharmacol. 2019;85(1):71–99. .
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Bali V, Carnahan RM, et al. Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Res Social Adm Pharm. 2020;16(3):329–335. .
   PubMed Web of Science ®Google Scholar
• Kalisch Ellett LM, Pratt NL, Ramsay EN, et al. Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia. J Am Geriatr Soc. 2014;62(10):1916–1922. .
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Bali V, Carnahan RM, et al. Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. Am J Geriatr Psychiatry. 2016;24(6):485–495. .
   PubMed Web of Science ®Google Scholar
• Chuang YF, Elango P, Gonzalez CE, et al. Midlife anticholinergic drug use, risk of Alzheimer’s disease, and brain atrophy in community-dwelling older adults. Alzheimers Dement (N Y). 2017;3(3):471–479. .
   PubMedGoogle Scholar
• Grossi CM, Richardson K, Fox C, et al. Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study. BMC Geriatr. 2019;19(1):276. .
   PubMed Web of Science ®Google Scholar
• Joung KI, Kim S, Cho YH, et al. Association of Anticholinergic Use with Incidence of Alzheimer’s Disease: population-based Cohort Study. Sci Rep. 2019;9(1):6802. .
   PubMedGoogle Scholar
• Hafdi M, Hoevenaar-Blom MP, Beishuizen CRL, et al. Association of Benzodiazepine and Anticholinergic Drug Usage With Incident Dementia: A Prospective Cohort Study of Community-Dwelling Older Adults. J Am Med Dir Assoc. 2020;21(2):188–193.e3. .
   PubMed Web of Science ®Google Scholar
• Wang YC, Chen Y-L, Huang -C-C, et al. Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study. BMC Geriatr. 2019;19(1):380. .
   PubMed Web of Science ®Google Scholar
• Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020. DOI:https://doi.org/10.1111/bju.15040
   Google Scholar
• Sivaprakasam K. Towards a unifying hypothesis of Alzheimer’s disease: cholinergic system linked to plaques, tangles and neuroinflammation. Curr Med Chem. 2006;13(18):2179–2188.
   PubMed Web of Science ®Google Scholar
• Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol. 2003;54(2):235–238. .
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Hanlon JT, et al. Exposure to Strong Anticholinergic Medications and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. J Alzheimers Dis. 2018;65(2):607–616. .
   PubMed Web of Science ®Google Scholar
• Guerriero F, Sgarlata C, Francis M, et al. Neuroinflammation, immune system and Alzheimer disease: searching for the missing link. Aging Clin Exp Res. 2017;29(5):821–831. .
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Panicker J, Fowler CJ, et al. Vascular incontinence: incontinence in the elderly due to ischemic white matter changes. Neurol Int. 2012;4(2):e13. .
   PubMedGoogle Scholar
• Faillie J-L. Indication bias or protopathic bias? Br J Clin Pharmacol. 2015;80(4):779–780.
   PubMed Web of Science ®Google Scholar
• Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. Am J Med. 1980;68(2):255–258.
   PubMed Web of Science ®Google Scholar
• Jano E, Aparasu RR. Healthcare outcomes associated with beers’ criteria: a systematic review. Ann Pharmacother. 2007;41(3):438–447.
   PubMed Web of Science ®Google Scholar
• Cordell CB, Borson S, Boustani M, et al. Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013;9(2):141–150. .
   PubMed Web of Science ®Google Scholar
• Ulfvarson J, Bastholm Rahmner P, Fastbom J, et al. Medication reviews with computerised expert support: evaluation of a method to improve the quality of drug utilisation in the elderly. Int J Health Care Qual Assur. 2010;23(6):571–582. .
   PubMedGoogle Scholar